이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Olfactory Function in Patients With Sinonasal Diseases: A Multicenter Observational Study

2026년 11월 10일 업데이트: Gustavo Subtil Magalhães Freire, University of Brasilia

Olfactory Profile of Patients With Sinonasal Diseases: A Multicenter Cross-Sectional Observational Study in Brazil

This multicenter, cross-sectional observational study aims to characterize olfactory function in patients with sinonasal diseases and investigate its associations with disease severity, clinical characteristics, and inflammatory markers. Olfactory function will be assessed using the MultiScent-20 digital odor identification test. Additional assessments will include sinonasal symptom severity, quality of life, endoscopic and radiological findings, and clinical and laboratory markers suggestive of type 2 inflammation. Healthy volunteers without olfactory complaints will serve as a comparison group. The study is expected to enroll 3,800 participants across participating centers in Brazil.

연구 개요

상세 설명

This is a multicenter, cross-sectional observational study conducted in Brazilian outpatient otolaryngology settings. The study aims to investigate olfactory function in patients with chronic rhinosinusitis and other sinonasal diseases and to explore its associations with clinical manifestations, disease severity, and inflammatory characteristics.

Olfactory function will be objectively assessed using the MultiScent-20 digital odor identification test, which provides a score ranging from 0 to 20, with higher scores indicating better olfactory performance. Participants will undergo a single study assessment.

Clinical data will include sinonasal symptoms, SNOT-22 scores, visual analog scale ratings, nasal polyp scores, previous sinonasal surgeries, relevant comorbidities, and alcohol intolerance. Laboratory, histopathological, and imaging findings obtained during routine clinical care within the predefined eligibility window will be collected when available.

Criteria suggestive of type 2 inflammation will be evaluated using predefined clinical and laboratory characteristics. Missing clinical or laboratory information will not constitute an exclusion criterion. Analyses involving individual variables will include participants with the corresponding available data, whereas the total count of type 2 inflammatory criteria will be calculated only when all eight criteria have been assessed.

A comparison group of healthy volunteers without olfactory complaints will also be included. No therapeutic intervention will be administered as part of this observational study.

연구 유형

관찰

등록 (추정된)

3800

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Estado de Bahia
      • Salvador, Estado de Bahia, 브라질
        • 모병
        • Hospital Universitário Professor Edgard Santos (HUPES)
    • Federal District
      • Brasília, Federal District, 브라질
        • 모병
        • Hospital Universitário de Brasília (HUB)
    • Goiás
      • Goiânia, Goiás, 브라질
        • 모병
        • Hospital das Clínicas da UFG
    • Paraná
      • Curitiba, Paraná, 브라질
        • 모병
        • Hospital IPO - sede Água Verde
    • Pernambuco
      • Recife, Pernambuco, 브라질
        • 모병
        • Hospital das Clínicas da UFPE
    • Piauí
      • Teresina, Piauí, 브라질
        • 모병
        • Hospital Getúlio Vargas (HGV)
    • Rio Grande do Sul
      • Canoas, Rio Grande do Sul, 브라질
        • 모병
        • Hospital Universitário Canoas
      • Porto Alegre, Rio Grande do Sul, 브라질
        • 모병
        • Hospital de Clínicas de Porto Alegre (HCPA)
    • Rio de Janeiro
      • Rio de Janeiro, Rio de Janeiro, 브라질
        • 모병
        • Hospital Universitário Pedro Ernesto
    • São Paulo
      • Ribeirão Preto, São Paulo, 브라질
        • 모병
        • Hospital das Clínicas da FMRP-USP - Campus
      • São Paulo, São Paulo, 브라질
        • 모병
        • Hospital das Clínicas da FMUSP
      • São Paulo, São Paulo, 브라질
        • 모병
        • Hospital São Paulo - Hospital Universitário da UNIFESP

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Adults aged 18 years or older with chronic rhinosinusitis or other sinonasal diseases and healthy volunteers without olfactory complaints, recruited at participating outpatient centers in Brazil.

설명

Inclusion Criteria:

Adults aged 18 years or older. Patients with chronic rhinosinusitis or other sinonasal diseases, or healthy volunteers without olfactory complaints participating in the comparison group.

Ability to understand and complete the study assessments.

Exclusion Criteria:

Illiteracy. Respiratory tract infection within the preceding seven days. Sinonasal surgery within the preceding six months. History of severe head trauma. Diagnosis of a neurodegenerative disease.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: OTHER
  • 시간 관점: CROSS_SECTIONAL

코호트 및 개입

그룹/코호트
Sinonasal Disease Participants

Adults with chronic rhinosinusitis or other sinonasal diseases.

Healthy Comparison Participants

Healthy adults without olfactory complaints.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
MultiScent-20 odor identification score
기간: Once at enrollment (cross-sectional assessment).

Total number of correctly identified odors on the 20-item MultiScent-20 digital odor identification test. Scores range from 0 to 20; higher scores indicate better odor identification performance.

Once at enrollment (cross-sectional assessment).

2차 결과 측정

결과 측정
측정값 설명
기간
Sinonasal Outcome Test-22 (SNOT-22) total score
기간: Once at enrollment (cross-sectional assessment).

Patient-reported sinonasal symptom burden assessed using the 22-item SNOT-22 questionnaire. Total scores range from 0 to 110; higher scores indicate greater symptom burden.

Once at enrollment (cross-sectional assessment).
Severity of four sinonasal symptoms on visual analog scales
기간: Once at enrollment (cross-sectional assessment).

Severity will be assessed separately for nasal obstruction, rhinorrhea, facial pain or pressure, and olfactory dysfunction using four individual visual analog scales (VAS). Each score ranges from 0 (no symptoms) to 10 (maximum symptom intensity). Each symptom score will be analyzed in relation to the MultiScent-20 odor identification score. No combined VAS total score is prespecified.

Once at enrollment (cross-sectional assessment).
Nasal Polyp Score (NPS)
기간: At enrollment, using available routine clinical assessment.

Endoscopic nasal polyp burden assessed using the Nasal Polyp Score, ranging from 0 to 8; higher scores indicate greater polyp burden. Applicable to participants with available endoscopic assessment.

At enrollment, using available routine clinical assessment.
Lund-Mackay computed tomography score
기간: At enrollment; CT performed within the 12 months preceding enrollment, if available.

Extent of sinonasal opacification on computed tomography evaluated using the Lund-Mackay scoring system (total score 0-24; higher scores indicate more extensive radiologic disease). Assessed when routine-care imaging is available.

At enrollment; CT performed within the 12 months preceding enrollment, if available.
Peripheral blood eosinophil count
기간: At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.

Absolute peripheral blood eosinophil count obtained from available routine-care laboratory testing.

At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
Total serum immunoglobulin E (IgE)
기간: At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.

Total serum IgE concentration obtained from available routine-care laboratory testing.

At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
Number of clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis
기간: Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.

Count of predefined clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis, according to the guideline for use of biologics in chronic rhinosinusitis with nasal polyps cited in the study protocol. Clinical criteria: symptom onset between ages 30 and 50 years; marked improvement in olfaction following oral corticosteroid use; adult-onset asthma; aspirin or nonsteroidal anti-inflammatory drug intolerance; and bilateral nasal polyps associated with thick allergic- or eosinophilic-appearing nasal mucus, preferably confirmed by nasal endoscopy. Biomarker criteria: tissue eosinophils ≥10 cells/high-power field; blood eosinophils ≥250 cells/µL; or total serum IgE ≥100 IU/mL. The total number of criteria suggestive of type 2 inflammation will be calculated only for participants with complete data on all eight clinical and laboratory criteria. The count ranges from 0 to 8 and equals the number of positive criteria.

Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.
Presence of selected comorbidities
기간: Once at enrollment (cross-sectional assessment).

Presence or absence of relevant comorbidities, including asthma and aspirin-exacerbated respiratory disease (AERD), recorded from clinical history.

Once at enrollment (cross-sectional assessment).
Number of previous sinonasal surgeries
기간: Once at enrollment (cross-sectional assessment).

The number of previous sinonasal surgeries will be recorded for each participant.

Once at enrollment (cross-sectional assessment).
Alcohol intolerance
기간: Once at enrollment (cross-sectional assessment).

Alcohol intolerance will be assessed as a binary variable (yes/no), based on self-reported nasal symptoms following the consumption of alcoholic beverages.

Once at enrollment (cross-sectional assessment).

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Gustavo Subtil M. Freire, University of Brasilia

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 3월 1일

기본 완료 (추정된)

2027년 11월 1일

연구 완료 (추정된)

2027년 11월 1일

연구 등록 날짜

최초 제출

2026년 11월 10일

QC 기준을 충족하는 최초 제출

2026년 11월 10일

처음 게시됨 (실제)

2026년 11월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • UNB-OLFATO-RSC-2026
  • 68687423.5.0000.5558 (기타 식별자: Brazilian Research Ethics CAAE)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다